Survodutide is a 29-amino-acid peptide built on a modified human glucagon sequence, with a fatty acid chain attached to extend its time in circulation. It has been tested in obesity, type 2 diabetes and fatty liver disease. Its first phase 3 obesity trials and a cardiovascular safety trial were published in 2026.
Quick answer: Survodutide is an investigational peptide drug in late-stage trials for obesity and the liver disease MASH. Survodutide is not approved by the FDA for any use. FDA has warned companies that sold survodutide labeled for research purposes directly to consumers. A research label does not make such material an approved medicine.
Vitrapep does not sell survodutide; this page is a reference summary of published research and regulatory information.
What is survodutide and how is it built?
Boehringer Ingelheim scientists described survodutide in 2022 under the code BI 456906. The paper says it was co-invented with Zealand Pharma [2].
The rationale comes from oxyntomodulin, a natural 37-amino-acid gut hormone. Oxyntomodulin weakly activates both the glucagon receptor and the GLP-1 receptor. In human studies cited by the authors, it reduced body weight and food intake and raised energy expenditure [2].
Survodutide has 29 amino acids based on the human glucagon sequence, with changes that balance activity at the two receptors [2]. PubChem lists the sequence as His-Ac4c-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Glu-Arg-Ala-Ala-Lys-Asp-Phe-Ile-Lys-Trp-Leu-Glu-Ser-Ala, with an amidated end [1].
Three features stand out. Position 2 carries 1-aminocyclobutane-1-carboxylic acid (Ac4c), a non-coded amino acid placed where the enzyme DPP-4 normally cuts [2]. The lysine at position 24 carries a glycine-serine linker and a C18 diacid [1], [2]. That fatty acid binds albumin, which lengthens the peptide's half-life [2].
What is survodutide and how is it built
| Property | Survodutide |
|---|---|
| Class | Dual glucagon receptor and GLP-1 receptor agonist; acylated peptide [2] |
| Length | 29 amino acids, based on a modified human glucagon sequence [2] |
| Key modifications | Ac4c at position 2; glycine-serine linker with a C18 diacid at position 24; amidated C-terminus [1], [2] |
| Molecular formula | C192H289N47O61 [1] |
| Molecular weight | 4,232 g/mol (PubChem computed value) [1] |
| Identifiers | Code BI 456906; CAS 2805997-46-8 [1]; FDA UNII 2ALA66NS64 |
| Mean residence time in animals | 44 hours in mice and 140 hours in dogs [2] |
| Developer | Boehringer Ingelheim, licensed from Zealand Pharma [12] |
| FDA approval | None; openFDA returned no Drugs@FDA record on November 18, 2026 |
How does survodutide work?
Survodutide activates two receptors in the glucagon family. The GLP-1 receptor supports glucose-dependent insulin release, slows stomach emptying and signals fullness (see what GLP-1 is). The glucagon receptor acts mainly in the liver (see the glucagon complete guide).
Cell findings. In one cell assay, survodutide was roughly 10-fold less potent than native GLP-1 and glucagon at their receptors [2].
Animal findings. In mice, survodutide reduced body weight more than semaglutide at its maximally effective level. The weight loss came from higher energy expenditure and lower food intake [2]. Liver gene expression, plasma amino acids and FGF-21 changed in ways that signal glucagon receptor activity. Studies in GLP-1 receptor knockout mice supported activity at both receptors [2].
Human findings. In phase 1 studies, survodutide lowered plasma amino acids and glucagon. The investigators read this as evidence of engagement at both receptors [3]. Retatrutide adds a third receptor, GIP, to the same glucagon and GLP-1 pair (see the retatrutide complete guide).
What is survodutide being studied for?
With no approved use, there is no label indication to cite. ClinicalTrials.gov listed 37 survodutide studies on November 18, 2026, in three main areas.
Obesity and overweight. SYNCHRONIZE-1 (NCT06066515), SYNCHRONIZE-2 (NCT06066528) and SYNCHRONIZE-CVOT (NCT06077864) are complete. Newer phase 3 trials include SYNCHRONIZE-HERA in women around menopause (NCT07850050).
Liver disease. MASH is metabolic dysfunction-associated steatohepatitis, a fatty liver disease with inflammation. LIVERAGE (NCT06632444) is recruiting an estimated 1,800 adults with moderate or advanced fibrosis. LIVERAGE-Cirrhosis (NCT06632457) plans about 1,590 adults with compensated cirrhosis.
Boehringer says LIVERAGE first measures MASH resolution and fibrosis improvement at 52 weeks. A second part follows liver-related events or death for about 7 years [12]. LIVERAGE-Cirrhosis runs about four and a half years [12].
Type 2 diabetes and kidney disease. A phase 3 glucose-control trial is recruiting (NCT07754461). ARTIST-CKD, a phase 2 trial on albuminuria in kidney disease, is not yet recruiting (NCT07206290). Vitrapep's guide on how to find a peptide clinical trial explains how to read these records.
What did the key survodutide trials show?
Phase 2 obesity trial (NCT04667377). The trial enrolled 387 adults without diabetes at 43 centers. Weight loss rose with dose level. Only 60.4% completed treatment, 61% on survodutide and 60% on placebo [4].
Phase 2 MASH trial (NCT04771273). Adults had biopsy-confirmed MASH with fibrosis stage F1 to F3. Liver fat fell by at least 30% in 57% to 67% of survodutide groups, versus 14% on placebo. Fibrosis improved by at least one stage in 34% to 36%, versus 22% [5].
SYNCHRONIZE-1. Adults had obesity, or overweight with a related complication, and no diabetes. Mean baseline weight was 108.8 kg. At least 5% weight loss occurred in 72.6% and 71.9% of the two survodutide groups, versus 46.3% on placebo [8].
SYNCHRONIZE-2. Participants had type 2 diabetes, with a mean baseline HbA1c of 7.4% [9].
SYNCHRONIZE-CVOT. This event-driven safety trial ran at 524 sites in 34 countries. Its composite endpoint covered cardiovascular death, nonfatal stroke, nonfatal heart attack, ischemia-related coronary revascularization and heart failure events. The noninferiority margin was a hazard ratio of 1.65 [10].
What did the key survodutide trials show
| Trial | Population and size | Design and length | Primary result |
|---|---|---|---|
| Phase 2 obesity, 2024 [4] | 386 treated adults with BMI 27 or more, no diabetes | Double-blind, placebo-controlled, four dose levels; 46 weeks | Weight fell 6.2% to 14.9% across dose groups vs 2.8% on placebo |
| Phase 2 MASH, 2024 [5] | 293 treated adults with MASH and fibrosis F1 to F3 | Double-blind, placebo-controlled, three dose levels; 48 weeks | MASH improved without fibrosis worsening in 47%, 62% and 43% vs 14% |
| SYNCHRONIZE-1, 2026 [8] | 725 adults with obesity or overweight, no diabetes | Double-blind, placebo-controlled, two dose levels; 76 weeks | Weight fell 12.2% and 13.0% vs 5.4% on placebo |
| SYNCHRONIZE-2, 2026 [9] | 752 adults with obesity or overweight and type 2 diabetes | Double-blind, placebo-controlled, two dose levels; 76 weeks | Weight fell 8.2% and 9.8% vs 3.9%; HbA1c fell 0.9 and 0.8 points vs 0.2 |
| SYNCHRONIZE-CVOT, 2026 [10] | 5,507 treated adults with BMI 27 or more and heart disease, kidney disease or risk factors | Double-blind, placebo-controlled, event-driven; median 22.0 months in study | Primary events 3.7% vs 4.1%; hazard ratio 0.89 (95% CI, 0.67 to 1.18); noninferior |
The phase 3 results use the treatment-regimen estimand. It counts outcomes whether or not participants stopped treatment early [8], [10].
In SYNCHRONIZE-MASLD, 216 adults with obesity and at-risk fatty liver disease were treated for 48 weeks. Liver fat fell by at least 30% in 68.5% on survodutide versus 28.6% on placebo [11]. A 16-week phase 2 trial in 413 adults with type 2 diabetes reported HbA1c falls of up to 1.71 points [6]. An open-label phase 1 study found similar drug exposure in people with cirrhosis and in healthy volunteers [7].
What side effects have survodutide trials reported?
Survodutide has no FDA label, boxed warning or label section 6. All safety data below come from trial publications, mostly funded by Boehringer Ingelheim.
Gastrointestinal events. These were the most common adverse events in SYNCHRONIZE-1 and SYNCHRONIZE-2 [8], [9]. In SYNCHRONIZE-1, they occurred in 80.9% and 89.7% of the survodutide groups, versus 47.9% on placebo. No deaths were reported [8]. In SYNCHRONIZE-2, the figures were 72.8% and 77.7%, versus 38.6% [9]. In the phase 2 MASH trial, nausea occurred in 66% versus 23%, and vomiting in 41% versus 4% [5].
Stopping treatment. SYNCHRONIZE-CVOT gives the largest dataset, shown below. About one in five survodutide participants stopped treatment because of gastrointestinal events [10]. In the phase 2 diabetes trial, most stops for adverse events came within the first 6 weeks [6].
What side effects have survodutide trials reported
| Event in SYNCHRONIZE-CVOT [10] | Survodutide, lower dose (N=1,836) | Survodutide, higher dose (N=1,835) | Placebo (N=1,836) |
|---|---|---|---|
| Any adverse event | 93.0% | 93.1% | 85.6% |
| Nausea | 48.0% | 49.0% | 12.1% |
| Vomiting | 31.7% | 34.0% | 4.8% |
| Stopped treatment for gastrointestinal events | 19.3% | 20.8% | 1.9% |
| Serious adverse events | 22.5% | 20.8% | 23.9% |
| Fatal adverse events | 0.9% | 0.9% | 0.6% |
Fatal events were mainly due to cardiac disorders, in 0.3% to 0.4% of each group [10].
Heart rate. In the 16-week diabetes trial, mean heart rate rose 2.3 to 7.3 beats per minute across survodutide groups. It rose 5.9 on semaglutide and 1.67 on placebo [6]. In SYNCHRONIZE-MASLD, the week 52 increase was 3.6 versus 0.8 beats per minute [11]. In an early phase 1 study, 7.5% of one cohort stopped because of a cardiac or vascular adverse event [3].
Other events. SYNCHRONIZE-MASLD found no adjudication-confirmed drug-induced liver injury, acute pancreatitis or thyroid cancer in the survodutide group [11]. Serious adverse events in the phase 2 MASH trial occurred in 8% versus 7% on placebo [5].
What is the regulatory status of survodutide?
Approval. Survodutide is not approved by the FDA for any use. The 2026 SYNCHRONIZE-2 report still describes it as investigational [9]. We found no approval by another regulator in the sources we checked.
Development designations. Boehringer reports that FDA granted Fast Track designation in May 2021 for non-cirrhotic MASH with moderate or advanced fibrosis [12]. In September 2024, FDA added a second designation, meant for serious conditions where early clinical evidence suggests substantial improvement over available treatments [12]. The European Medicines Agency accepted survodutide into its PRIME scheme in November 2023 [12]. These designations can speed review but are not approvals.
Research-labeled products. FDA says it has warned companies that illegally sold unapproved survodutide products. Their labels falsely said "for research purposes" or "not for human consumption," according to FDA. The products were sold directly to consumers for human use with dosing instructions [13]. Vitrapep's summary of FDA's August 2026 warning letters covers letters that name survodutide.
A research-use-only label does not make a product legal or safe for people. See research peptides and human-use risks and why research peptides have no dose.
Compounding. FDA's page says retatrutide and cagrilintide cannot be used in compounding but does not address survodutide there [13]. We found no other FDA compounding statement on it.
Sport. The WADA 2026 Prohibited List does not name survodutide. Its S0 class covers pharmacological substances not addressed elsewhere and without current regulatory approval for human therapeutic use, including drugs in clinical development [14]. See Vitrapep's WADA 2026 peptide reference.
What is still unknown about survodutide?
SYNCHRONIZE-CVOT was designed to rule out excess cardiovascular risk, not to show benefit. Its confidence interval includes no effect [10]. Liver outcome results from LIVERAGE and LIVERAGE-Cirrhosis are years away [12]. Among the published trials reviewed here, the only comparison with an approved medicine was an open-label semaglutide arm in one 16-week trial [6].
The cause and meaning of the heart rate rise over longer use is not established in the papers reviewed here. In SYNCHRONIZE-CVOT, only 56.0% to 59.0% of each group stayed on treatment until the end, which complicates long-term safety estimates [10].
Frequently asked questions
Is survodutide a peptide?
Yes. It is a 29-amino-acid acylated peptide with a PubChem molecular weight of about 4,232 g/mol.
Is survodutide FDA-approved?
No. It has no FDA approval for any use. FDA granted development designations for MASH, which are not approvals.
How is survodutide different from retatrutide?
Survodutide activates the glucagon and GLP-1 receptors. Retatrutide also activates the GIP receptor. Neither is FDA-approved.
What side effects were most common in survodutide trials?
Gastrointestinal events, mainly nausea, vomiting and diarrhea. In SYNCHRONIZE-CVOT, about one in five participants on survodutide stopped treatment because of them.
Who developed survodutide?
Boehringer Ingelheim develops it under a license from Zealand Pharma, which co-invented it. Boehringer sponsors and funds the trials.
Is research-grade survodutide the same as the trial drug?
Not necessarily. FDA says research-labeled survodutide sold to consumers is of unknown quality and may be harmful.
What to know now
- Survodutide is a 29-amino-acid peptide that activates the glucagon and GLP-1 receptors, with a C18 diacid that binds albumin.
- In SYNCHRONIZE-1, weight fell 12.2% and 13.0% over 76 weeks, versus 5.4% on placebo.
- SYNCHRONIZE-CVOT showed no increase in major cardiovascular events versus placebo, with frequent gastrointestinal side effects.
- Survodutide is not FDA-approved, and FDA has warned sellers of research-labeled survodutide.
What we’re watching
- Biopsy results from part one of LIVERAGE in MASH with moderate or advanced fibrosis.
- Any regulatory filing for obesity or MASH announced by Boehringer Ingelheim.
- Results from newer phase 3 trials in type 2 diabetes and in women around menopause.